Mobia Medical Finds the Limits of Medtech IPO Appetite

AUSTIN, Texas, May 10, 2026 — Mobia Medical is not another pre-revenue device filing trying to borrow the IPO window. The company came public with a commercial product, revenue that more than doubled in 2025, and a three-bank lead group that usually gives a medtech book real shape. Even so, the market’s first answer was cold: Mobia priced 10 million shares at $15, the midpoint of its range, and the stock closed May 8 at $11.75, down 21.7% on its Nasdaq debut.

That leaves the deal in a sharper light. Mobia is selling the first and only FDA-approved implantable Vivistim system for chronic ischemic stroke survivors with moderate to severe upper-extremity impairment, a niche that is clinically interesting and commercially difficult. The final prospectus shows 2025 revenue of $32.0 million, up from $15.6 million a year earlier, with gross margin improving to 81.1%. But net loss widened to $46.5 million from $24.6 million as the company kept building out commercialization.

The underwriting quality was there. BofA Securities, J.P. Morgan and Goldman Sachs led the book, with BTIG and Wolfe | Nomura Alliance also on the ticket. Mobia expects about $134.5 million in net proceeds, enough to push further into sales, clinical work and general corporate use. As of December 31, 2025, the company had about $33.6 million in cash, an 83-person direct sales team, and 255 participants enrolled across 59 sites in its GRASP registry. Post-offering, the basic share count sits at roughly 33.1 million, implying an IPO market value near $496 million at the offer price.

The catch is reimbursement, and that is where investors appear to have drawn the line. Mobia can point to a favorable Medicare payment change that took effect on January 1, 2026, but the prospectus also says most commercial insurers still treat Vivistim Therapy as experimental or investigational. For a company targeting an estimated 1,500 primary and comprehensive stroke centers in the U.S., that gap matters more than the syndicate list. Mobia has a real commercial story. The first day of trading suggests public investors still want harder evidence that coverage can broaden fast enough to justify the burn.